|[January 17, 2013]
Diamyd Medical: Recombinant vaccine from Protein Sciences receives FDA approval
STOCKHOLM --(Business Wire)--
The US Food and Drug Administration has approved Protein Sciences
Corporation's vaccine Flublok for the prevention of seasonal influenza
in adults 18 to 49 years of age. Diamyd Medical holds about 8 percent of
the shares in Protein Sciences Corporation.
Flublok is a recombinant protein-based seasonal influenza vaccine and
the first influenza vaccine manufactured using recombinant technology
that has received marketing approval by the FDA. Protein Sciences
Corporation is planning to have a limited launch of the product in
February 2013 with the full launch occurring in time for the 2013/14
influenza season. More information can be found at www.proteinsciences.com
About Protein Sciences Corporation
Protein Sciences Corporation, founded in 1983, is a privately held
biotechnology company located in Meriden, Connecticut, USA. The Company
focuses on the development and commercialization of recombinant vaccines
and biopharmaceuticals based on the Company's patented manufacturing
platform BEVS (Baculovirus Exression Vector System). Protein Sciences'
lead product candidates are Flublok against seasonal influenza, and
Panblok against pandemic influenza.
Protein Sciences is one of only a few companies in the world to develop
recombinant vaccines produced in non-mammalian cells using genetically
modified baculovirus. Some advantages compared to traditional vaccine
manufacturing are that it requires less lead time to manufacture, the
products are not produced in eggs and therefore do not contain egg
derivatives, and the manufacturing does not require the use of live
influenza virus, thimerosal or antibiotics.
Protein Sciences also partners with select companies on product
development and manufacturing, and sells proteins for research purposes.
The Company is for example the contract manufacturer of the active
ingredient GAD for Diamyd Medical's antigen-based diabetes therapy
Diamyd Medical holds about 8 percent of the shares in Protein Sciences
Corporation. On August 31, 2012, the carrying amount of this holding was
About Diamyd Medical
Diamyd Medical (STO:DIAMB) was founded in 1996 and is active in the
field of pharmaceutical development. Diamyd Medical is headquartered in
Stockholm, Sweden. The Company's development project consists of the
protein GAD65 for the treatment and prevention of autoimmune diabetes. A
Swedish researcher-initiated Phase II study is ongoing to evaluate
whether GAD65 can prevent type 1 diabetes in children who are at high
risk of developing the disease.
Diamyd Medical also has holdings in the gene therapy company Periphagen
Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation
(USA) and the diagnostics company Mercodia AB (Sweden).
Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm
(ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by
the Pink OTC Markets and the Bank of New York Mellon (PAL). Further
information is available on the Company's website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities
Markets Act, the Swedish Financial Instruments Trading Act, or the
requirements stated in the listing agreements.
Diamyd Medical AB (publ) Karlavägen 108, SE-115 26 Stockholm, Sweden.
Phone (News - Alert): +46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: email@example.com.
Reg. no: 556530-1420
This information was brought to you by Cision http://www.cisionwire.com
[ Back To Technology News's Homepage ]